Please login to the form below

How we’re empowering our teams to fight healthcare inequality

Welcoming Sheena Amin-Liebman as our new Diversity and Inclusion Director. Sheena will play a vital role in creating an inspiring environment that empowers staff to better guide its clients in their work to improve health outcomes for the patients they serve.

Inequality is pervasive in the healthcare systems across the globe, disproportionately impacting people of color and other marginalized groups. From lower life expectancy to racial disparities in maternal care and challenges accessing treatment, it’s clear people of color face barriers preventing them from fully benefiting from treatment and care across the entire spectrum of their lives.

Inequalities are often evident in the way therapies and life science services are developed. As a result, many companies have pledged to better support marginalized patients through research and development, by developing strategies to improve access, and through the development of more inclusive medical affairs and marketing tactics.

At Fishawack Health, our goal is to help our clients deeply understand, reach, and engage the patients they serve, including marginalized groups. We are working hard to develop a culture that empowers our team members to recognize inequalities. Our ambition is to equip our teams with the knowledge and skills to uncover opportunities that help our life science clients develop better solutions for diverse patient populations.

Today, we have reached a milestone in our journey: appointing Sheena Amin-Liebman in the newly created role of Diversity & Inclusion (D&I) Director. Sheena will lead Fishawack Health’s D&I objectives and drive change across its multiple locations globally.


3rd November 2021



Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

No. 3 Booths Park
Booths Hall
Chelford Road
WA16 8GS
United Kingdom

Latest content on this profile

Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health
Omnichannel scientific engagement and the use of archetypes to drive personalization
Natasha Cowan, Senior Corporate Communications Manager, explores with Gary Lyons, Head of Strategy, his recent plenary session at the 18th Annual ISMPP conference that focused on how scientific communicators can use archetypes to segment their audience and develop personalized learning journeys for healthcare professionals.
Fishawack Health
The promised land of gene therapy: Commercialization of novel gene-editing technology in beta-thalassemia
With transformative treatments that leverage CRISPR technology, there are many challenges to overcome throughout the journey of development through to patient access. We interviewed a researcher at a top 20 pharma company, multiple patients, and our own market access experts for their insights into the process, obstacles, and opportunities for biopharmaceutical companies to meet patient needs and achieve success in the market.
Fishawack Health
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of stakeholders earlier than you think.
Fishawack Health
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence generation to support the design of an asset.
Fishawack Health